The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government
has recently announced $1.1 billion in funding for comparative effectiveness research (CER)
as part of its planned overhaul of the U.S. healthcare system. Payers in all markets will increasingly
compare new drugs with established therapies and offer the most favorable pricing and reimbursement
terms only to drugs that are deemed innovative.
Questions Answered in This Report:
HTA has become a major focus of attention in healthcare systems around the world in recent years.
What are the key elements of HTA? What approaches have the authorities in leading pharmaceutical
markets taken to the use of HTA?
European governments have used various forms of HTA for many years. How do HTA strategies
vary from one European country to another? What common trends can be observed in
Europe?
The United States has been much slower than other mature pharmaceutical markets to embrace
HTA. Which U.S. organizations have practiced HTA in the past? What action has the U.S.
government recently taken to stimulate greater use of CER in the United States?
Scope:
Increasing focus on HTA: defi nitions of HTA; role of health economic evaluation; strategies
in major markets.
Use of HTA in leading markets: France; Germany; Italy; Spain; United Kingdom; United
States; international collaborations.
Outlook and implications for the pharmaceutical industry: European industry’s key
principles for HTA; challenges presented by the adoption of CER in the United States; key
message to payers.
(0 items)
